Research Article
Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines
Figure 2
Cotreatment of gilteritinib and HHT impaired the MMP and activated an intrinsic apoptotic pathway. (a, b) Percentage of JC-1 monomers. MV4-11 cells (a) and Molm13 cells (b) were given a treatment of gilteritinib and/or HHT for 24 hours. The cells treated with DMSO were used as a control group. (c, d) Western blot analysis of PARP, cleaved PARP, Mcl-1, Bcl-2, Bax, and Bak in treated MV4-11 cells (c) and Molm13 cells (d). (e, f) Quantification of (c) and (d); each group was equated with the control group. , , and .
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |